The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Search for "plaque psoriasis"

Search results for: plaque psoriasis

Study Finds Mirikizumab Superior to Secukinumab for Plaque Psoriasis

August 7, 2020 • By Michele B. Kaufman, PharmD, BCGP

In a comparison study, subcutaneous mirikizumab proved superior to subcutaneous in achieving skin clearance in patients with plaque psoriasis…... [Read More]

Filed Under: Biologics & Biosimilars, Drug Updates Tagged With: mirikizumab, plaque psoriasis, secukinumab

Apremilast Promising for Plaque Psoriasis

July 6, 2020 • By Michele B. Kaufman, PharmD, BCGP

Apremilast has been shown to improve the signs and symptoms of mild to moderate plaque psoriasis in adults, according to new research…... [Read More]

Filed Under: Analgesics, Drug Updates Tagged With: apremilast, plaque psoriasis, skin

Risankizumab Demonstrates Superiority to Secukinumab for Plaque Psoriasis

February 5, 2020 • By Michele B. Kaufman, PharmD, BCGP

In a phase 3, comparator study in adults with plaque psoriasis, patients taking
risankizumab achieved greater skin clearance than those taking secukinumab…... [Read More]

Filed Under: DMARDs & Immunosuppressives, Drug Updates Tagged With: plaque psoriasis, risankizumab, secukinumab

IV Meloxicam Stalls at FDA; Plus Health Canada Approves Risankizumab for Plaque Psoriasis

May 14, 2019 • By Michele B. Kaufman, PharmD, BCGP

In a second response letter, the FDA has cited the onset and duration of intravenous meloxicam, a non-opioid pain treatment, as concerns that it fails to meet prescriber expectations…... [Read More]

Filed Under: Analgesics, Biologics & Biosimilars, Drug Updates Tagged With: Canada, FDA, meloxicam, non-opioid pain shot, Pain, plaque psoriasis, rizankixumab, U.S. Food and Drug Administration (FDA)

Mirikizumab Promising for Plaque Psoriasis

April 10, 2019 • By Michele B. Kaufman, PharmD, BCGP

During a 16-week study, patients with plaque psoriasis taking mirikizumab experienced higher response rates and skin clearance compared with placebo…... [Read More]

Filed Under: Biologics & Biosimilars, Drug Updates Tagged With: mirikizumab, plaque psoriasis, skin

FDA Update: Topical Plaque Psoriasis Treatment Approved; Dupilumab Will Receive FDA Priority Review

December 3, 2018 • By Michele B. Kaufman, PharmD, BCGP

The FDA has approved halobetasol propionate lotion as a topical treatment for plaque psoriasis…... [Read More]

Filed Under: DMARDs & Immunosuppressives, Drug Updates Tagged With: dermatitis, dupilumab, FDA, halobetasol propionate lotion, plaque psoriasis, U.S. Food and Drug Administration (FDA)

Plaque Psoriasis Treatments: BMS-986165 Promising & Adalimumab Biosimilar Demonstrates Equivalence

October 22, 2018 • By Michele B. Kaufman, PharmD, BCGP

According to new data, BMS-986165, an oral, selective tyrosine kinase 2 inhibitor, may be safe and effective for treating plaque psoriasis…... [Read More]

Filed Under: Biologics & Biosimilars, DMARDs & Immunosuppressives, Drug Updates Tagged With: adalimumab, adalimumab-adbm, BMS-986165, plaque psoriasis, TYK2 inhibitor, tyrosine kinase 2 inhibitor

FDA Approves Combination Therapy for OA Pain, but Not Duobrii Lotion for Plaque Psoriasis

July 9, 2018 • By Michele B. Kaufman, PharmD, BCGP

The FDA has approved a combination of amlodipine and celecoxib, which may lower serum creatinine, for treating osteoarthritis pain and hypertension…... [Read More]

Filed Under: Analgesics, DMARDs & Immunosuppressives, Drug Updates Tagged With: Consensi, Duobrii, FDA approval, hypertension, osteoarthritis (OA), Pain, Pain Management, U.S. Food and Drug Administration (FDA)

Certolizumab Pegol Receives FDA Approval for Plaque Psoriasis

June 18, 2018 • By Michele B. Kaufman, PharmD, BCGP

On the basis of data from multiple clinical trials, the FDA has approved certolizumab pegol for treating moderate to severe plaque psoriasis…... [Read More]

Filed Under: DMARDs & Immunosuppressives, Drug Updates Tagged With: Certolizumab Pegol, FDA, FDA approval, plaque psoriasis, Psoriasis, U.S. Food and Drug Administration (FDA)

Ustekinumab Approved for Use in Adolescents with Plaque Psoriasis

November 3, 2017 • By Michele B. Kaufman, PharmD, BCGP

In October, the FDA approved ustekinumab to treat patients 12 years or older who have moderate to severe plaque psoriasis…... [Read More]

Filed Under: DMARDs & Immunosuppressives, Drug Updates Tagged With: adolescent, FDA, plaque psoriasis, Psoriasis, U.S. Food and Drug Administration (FDA), ustekinumab

  • 1
  • 2
  • 3
  • …
  • 19
  • Next Page »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)